224 related articles for article (PubMed ID: 31740764)
1. Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens.
Parker EN; Drown BS; Geddes EJ; Lee HY; Ismail N; Lau GW; Hergenrother PJ
Nat Microbiol; 2020 Jan; 5(1):67-75. PubMed ID: 31740764
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel and potent class of FabI-directed antibacterial agents.
Payne DJ; Miller WH; Berry V; Brosky J; Burgess WJ; Chen E; DeWolf WE; Fosberry AP; Greenwood R; Head MS; Heerding DA; Janson CA; Jaworski DD; Keller PM; Manley PJ; Moore TD; Newlander KA; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Salyers KL; Seefeld MA; Smyth MG; Takata DT; Uzinskas IN; Vaidya K; Wallis NG; Winram SB; Yuan CC; Huffman WF
Antimicrob Agents Chemother; 2002 Oct; 46(10):3118-24. PubMed ID: 12234833
[TBL] [Abstract][Full Text] [Related]
3. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.
Schiebel J; Chang A; Shah S; Lu Y; Liu L; Pan P; Hirschbeck MW; Tareilus M; Eltschkner S; Yu W; Cummings JE; Knudson SE; Bommineni GR; Walker SG; Slayden RA; Sotriffer CA; Tonge PJ; Kisker C
J Biol Chem; 2014 Jun; 289(23):15987-6005. PubMed ID: 24739388
[TBL] [Abstract][Full Text] [Related]
4. Facilitating Compound Entry as a Means to Discover Antibiotics for Gram-Negative Bacteria.
Muñoz KA; Hergenrother PJ
Acc Chem Res; 2021 Mar; 54(6):1322-1333. PubMed ID: 33635073
[TBL] [Abstract][Full Text] [Related]
5. A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii.
Kwon J; Mistry T; Ren J; Johnson ME; Mehboob S
Bioorg Med Chem; 2018 Jan; 26(1):65-76. PubMed ID: 29162308
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis.
Karlowsky JA; Laing NM; Baudry T; Kaplan N; Vaughan D; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2007 Apr; 51(4):1580-1. PubMed ID: 17220418
[No Abstract] [Full Text] [Related]
7. Ternary complex formation of AFN-1252 with Acinetobacter baumannii FabI and NADH: Crystallographic and biochemical studies.
Rao NK; Nataraj V; Ravi M; Panchariya L; Palai K; Talapati SR; Lakshminarasimhan A; Ramachandra M; Antony T
Chem Biol Drug Des; 2020 Aug; 96(2):704-713. PubMed ID: 32227402
[TBL] [Abstract][Full Text] [Related]
8. FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors.
Rana P; Ghouse SM; Akunuri R; Madhavi YV; Chopra S; Nanduri S
Eur J Med Chem; 2020 Dec; 208():112757. PubMed ID: 32883635
[TBL] [Abstract][Full Text] [Related]
9. Fungal naphtho-γ-pyrones: Potent antibiotics for drug-resistant microbial pathogens.
He Y; Tian J; Chen X; Sun W; Zhu H; Li Q; Lei L; Yao G; Xue Y; Wang J; Li H; Zhang Y
Sci Rep; 2016 Apr; 6():24291. PubMed ID: 27063778
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
Kim YG; Seo JH; Kwak JH; Shin KJ
Bioorg Med Chem Lett; 2015 Oct; 25(20):4481-6. PubMed ID: 26343826
[TBL] [Abstract][Full Text] [Related]
11. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
Karlowsky JA; Kaplan N; Hafkin B; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2009 Aug; 53(8):3544-8. PubMed ID: 19487444
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.
Takahata S; Iida M; Yoshida T; Kumura K; Kitagawa H; Hoshiko S
J Antibiot (Tokyo); 2007 Feb; 60(2):123-8. PubMed ID: 17420562
[TBL] [Abstract][Full Text] [Related]
13. Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI).
Mehboob S; Song J; Hevener KE; Su PC; Boci T; Brubaker L; Truong L; Mistry T; Deng J; Cook JL; Santarsiero BD; Ghosh AK; Johnson ME
Bioorg Med Chem Lett; 2015 Mar; 25(6):1292-6. PubMed ID: 25677657
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
Lu H; Tonge PJ
Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
[TBL] [Abstract][Full Text] [Related]
15. Ebselen bearing polar functionality: Identification of potent antibacterial agents against multidrug-resistant Gram-negative bacteria.
Chen C; Yang K
Bioorg Chem; 2019 Dec; 93():103286. PubMed ID: 31585265
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections.
Tan L; Tao Y; Wang T; Zou F; Zhang S; Kou Q; Niu A; Chen Q; Chu W; Chen X; Wang H; Yang Y
J Med Chem; 2017 Apr; 60(7):2669-2684. PubMed ID: 28287720
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.
Seefeld MA; Miller WH; Newlander KA; Burgess WJ; Payne DJ; Rittenhouse SF; Moore TD; DeWolf WE; Keller PM; Qiu X; Janson CA; Vaidya K; Fosberry AP; Smyth MG; Jaworski DD; Slater-Radosti C; Huffman WF
Bioorg Med Chem Lett; 2001 Sep; 11(17):2241-4. PubMed ID: 11527706
[TBL] [Abstract][Full Text] [Related]
18. Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.
Zheng CJ; Sohn MJ; Lee S; Kim WG
PLoS One; 2013; 8(11):e78922. PubMed ID: 24312171
[TBL] [Abstract][Full Text] [Related]
19. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.
Park HS; Yoon YM; Jung SJ; Kim CM; Kim JM; Kwak JH
J Antimicrob Chemother; 2007 Sep; 60(3):568-74. PubMed ID: 17606482
[TBL] [Abstract][Full Text] [Related]
20. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).
Heerding DA; Chan G; DeWolf WE; Fosberry AP; Janson CA; Jaworski DD; McManus E; Miller WH; Moore TD; Payne DJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Smith W; Takata DT; Vaidya KS; Yuan CC; Huffman WF
Bioorg Med Chem Lett; 2001 Aug; 11(16):2061-5. PubMed ID: 11514139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
